Literature DB >> 16489686

Hepatic adenomatosis associated with hormone replacement therapy and hemosiderosis: a case report.

Satoshi Hagiwara1, Hitoshi Takagi, Daisuke Kanda, Naondo Sohara, Satoru Kakizaki, Kenji Katakai, Teruo Yoshinaga, Tsugio Higuchi, Kenichi Nomoto, Hiroyuki Kuwano, Masatomo Mori.   

Abstract

We have reported a case of hepatic adenomatosis associated with hormone replacement therapy (estrogen and progesterone) and hemosiderosis caused by excessive blood transfusion for the treatment of chronic myeloid leukemia. A 34-year-old woman was found to have several hepatic tumors on a routine medical examination. The general condition was good. Laboratory studies showed iron overload. Abdominal computed tomography and selective hepatic angiography showed several hypervascular tumors in the right lobe of the liver (up to 20 mm in diameter). Since hepatocellular carcinoma could not be ruled out, subsegmental hepatectomy was performed. Histopathological examination of the surgical specimen showed hepatic adenomatosis with hemosiderosis. Both hormone replacement therapy and iron overload could be the cause of hepatic adenomatosis.

Entities:  

Mesh:

Year:  2006        PMID: 16489686      PMCID: PMC4066105          DOI: 10.3748/wjg.v12.i4.652

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  13 in total

1.  Release of iron from ferritin storage by redox cycling of stilbene and steroid estrogen metabolites: a mechanism of induction of free radical damage by estrogen.

Authors:  S Wyllie; J G Liehr
Journal:  Arch Biochem Biophys       Date:  1997-10-15       Impact factor: 4.013

2.  Hepatocellular adenomatosis associated with hereditary haemochromatosis.

Authors:  J M Radhi; J Loewy
Journal:  Postgrad Med J       Date:  2000-02       Impact factor: 2.401

3.  Possible association between benign hepatomas and oral contraceptives.

Authors:  J K Baum; J J Bookstein; F Holtz; E W Klein
Journal:  Lancet       Date:  1973-10-27       Impact factor: 79.321

4.  Complete regression of hepatocellular adenoma after withdrawal of oral contraceptives.

Authors:  U P Steinbrecher; R Lisbona; S N Huang; S Mishkin
Journal:  Dig Dis Sci       Date:  1981-11       Impact factor: 3.199

Review 5.  Hemochromatosis: 1980 update.

Authors:  L W Powell; M L Bassett; J W Halliday
Journal:  Gastroenterology       Date:  1980-02       Impact factor: 22.682

Review 6.  Role of iron in estrogen-induced cancer.

Authors:  J G Liehr; J S Jones
Journal:  Curr Med Chem       Date:  2001-06       Impact factor: 4.530

7.  Hepatic adenomatosis: gadolinium-enhanced dynamic MR findings.

Authors:  M Kebapci; T Kaya; O Aslan; O Bor; E Entok
Journal:  Abdom Imaging       Date:  2001 May-Jun

8.  Liver adenomatosis: clinical, histopathologic, and imaging findings in 15 patients.

Authors:  L Grazioli; M P Federle; T Ichikawa; E Balzano; M Nalesnik; J Madariaga
Journal:  Radiology       Date:  2000-08       Impact factor: 11.105

9.  Liver adenomatosis. An entity distinct from liver adenoma?

Authors:  J F Flejou; J Barge; Y Menu; C Degott; H Bismuth; F Potet; J P Benhamou
Journal:  Gastroenterology       Date:  1985-11       Impact factor: 22.682

10.  Regression of liver cell adenoma. A follow-up study of three consecutive patients after discontinuation of oral contraceptive use.

Authors:  H Bühler; M Pirovino; A Akobiantz; J Altorfer; M Weitzel; E Maranta; M Schmid
Journal:  Gastroenterology       Date:  1982-04       Impact factor: 22.682

View more
  1 in total

1.  Benign Lesions of the Liver.

Authors:  K Rajender Reddy
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.